Osteosarcomas are the most frequent primary bone sarcomas, affecting mainly children,
adolescents, and young adults, and with a second peak of incidence in elderly individuals …

For the past 30 years, improvements in the survival of patients with osteosarcoma have been
mostly incremental. Despite evidence of genomic instability and a high frequency of …

Osteosarcoma is a highly aggressive cancer for which treatment has remained essentially
unchanged for more than 30 years. Osteosarcoma is characterized by widespread and …

Simple Summary Since the targeting of a single pro-angiogenic factor fails to improve
oncological disease outcome, significant efforts have been made to identify new pro …

Osteosarcoma (OS) is a highly malignant tumor occurring in bone tissue with a high
propensity to metastasize, and its underlying mechanisms remain largely elusive. The OS …

The vascular endothelial growth factor (VEGF) family members, VEGF-A, placenta growth
factor (PlGF), and to a lesser extent VEGF-B, play an essential role in tumor-associated …

Summary Background Patients with Ewing sarcoma or osteosarcoma have a median overall
survival of less than 12 months after diagnosis, and a standard treatment strategy has not yet …

Background Tyrosine kinase inhibitors have shown activity in osteosarcoma and might
enhance the efficacy of chemotherapy. We aimed to determine the recommended phase 2 …

Osteosarcoma (OS) is a highly aggressive pediatric cancer, characterized by frequent lung
metastasis and pathologic bone destruction. Vascular endothelial growth factor A (VEGFA) …

MicroRNAs (miRNAs) have been proven to be involved in cell metastasis and angiogenesis
by interaction with the target mRNAs. Evidence has been confirmed that miR-140-5p is a …